$ABBV (+1,05 %) | AbbVie Q3'24 Earnings Highlights:

🔹 Adj EPS: $3.00 (Est. $2.92) 🟢; UP +1.7% YoY

🔹 Revenue: $14.46B (Est. $14.28B) 🟢; UP +3.8% YoY

FY 2024 Guidance:

🔹 Adjusted EPS: $10.90-$10.94 (Est. $10.85) 🟡

🔹 Includes unfavorable $0.64/share impact from acquired IPR&D and milestones expense

Segment Revenue:

🔸 Immunology: $7.046B; UP +3.9% YoY

🔹 Humira: $2.227B; DOWN -37.2% YoY (U.S.: -41.6%, International: -12.4%)

🔹 Skyrizi: $3.205B; UP +50.8% YoY

🔹 Rinvoq: $1.614B; UP +45.3% YoY

🔸 Oncology: $1.687B; UP +11.6% YoY

🔹 Imbruvica: $828M; DOWN -8.8% YoY

🔹 Venclexta: $677M; UP +14.8% YoY

🔸 Neuroscience: $2.363B; UP +15.6% YoY

🔹 Botox Therapeutic: $848M; UP +13.4% YoY

🔹 Vraylar: $875M; UP +16.6% YoY

🔸 Aesthetics: $1.239B; DOWN -0.1% YoY

🔹 Botox Cosmetic: $671M; UP +8.2% YoY

🔹 Juvederm: $258M; DOWN -19.7% YoY

Profitability Metrics:

🔹 Gross Margin: 84.4% (Adjusted)

🔹 Operating Margin: 46.7% (Adjusted)

🔹 Net Interest Expense: $591M

🔹 Tax Rate: 16.2% (Adjusted)

Strategic Highlights:

🔸 Cerevel Acquisition: Adds complementary neuroscience assets.

🔸 Dividend Increase: +5.8% for 2025, effective February.

CEO Commentary:

🔸 "Strong execution and pipeline progress give us confidence to raise our full-year guidance and dividend."